NeuroPace reported Q4 2025 total revenue of USD 26.6 million (+24%) and FY 2025 total revenue of USD 100.0 million (+25%), driven by RNS System revenue of USD 22.4 million in Q4 (+26%) and USD 81.7 million in FY (+25%). Q4 2025 gross margin was 77.4% and FY 2025 gross margin was 77.2%. Q4 2025 operating expenses were USD 22.3 million, and NeuroPace posted a Q4 2025 operating loss of USD 1.8 million and a net loss of USD 2.7 million; FY 2025 net loss was USD 21.5 million. Adjusted EBITDA was USD 0.9 million in Q4 and (USD 5.0) million for FY 2025. Cash, cash equivalents and short-term investments were USD 61.1 million at December 31, 2025, and long-term borrowings were USD 58.9 million. In corporate updates, NeuroPace submitted a PMA-S to the FDA seeking expanded RNS System indication for IGE, supported by 18-month NAUTILUS trial results showing a 77% median seizure reduction. The company also cited favorable CY 2026 Medicare reimbursement updates, including a 47% increase for RNS System replacement reimbursement under OPPS starting January 1, 2026, and increases of approximately 43% (initial implant) and 45% (replacement) under the Medicare Physician Fee Schedule. NeuroPace submitted its Seizure ID AI tool to the FDA for review, highlighted more than 80 RNS System presentations at AES, and amended its distribution agreement with DIXI Medical to end partnership activities on December 31, 2025; it expects to report DIXI-related results as discontinued operations beginning in Q1 2026. For FY 2026 (continuing operations), NeuroPace reiterated revenue guidance of USD 98 million to USD 100 million and Adjusted EBITDA guidance of (USD 9.0) million to (USD 10.0) million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260303239810) on March 03, 2026, and is solely responsible for the information contained therein.